rubius
therapeutics
appoints
jose
carmona
chief
financial
officer
cambridge
globe
newswire
rubius
therapeutics
nasdaq
ruby
biopharmaceutical
company
genetically
engineering
red
blood
cells
create
entirely
new
class
cellular
medicines
today
announced
appointment
jose
pepe
carmona
chief
financial
officer
pepe
brings
years
experience
biopharmaceutical
industry
across
numerous
leadership
roles
geographies
therapeutic
areas
pepe
joins
rubius
therapeutics
period
excellent
progress
dose
escalate
patients
phase
solid
tumor
clinical
trial
per
plan
initiate
patient
recruitment
phase
relapsed
refractory
acute
myeloid
leukemia
trial
track
file
investigational
new
drug
application
first
artificial
cell
program
treatment
cancers
fully
owned
operational
manufacturing
facility
supply
clinical
trials
said
pablo
cagnoni
president
chief
executive
officer
pepe
extensive
experience
global
finance
operations
well
track
record
financing
commercial
biotech
companies
critical
begin
generate
clinical
data
advance
broad
pipeline
potentially
red
cell
treatment
cancer
autoimmune
pepe
recently
served
chief
financial
officer
radius
health
responsible
financial
aspects
business
well
investor
relations
business
development
operational
functions
prior
joining
radius
carmona
chief
financial
officer
innocoll
holdings
plc
acquired
gurnet
point
career
novartis
carmona
held
numerous
financial
management
positions
increasing
responsibilities
various
divisions
chief
financial
officer
europe
north
america
latin
america
held
senior
global
financial
roles
believe
rubius
therapeutics
science
pipeline
programs
poised
transform
cancer
autoimmune
diseases
treated
said
pepe
carmona
exciting
time
rubius
welcome
opportunity
join
leadership
team
contribute
towards
fostering
company
rubius
therapeutics
rubius
therapeutics
nasdaq
ruby
biopharmaceutical
company
genetically
engineering
red
blood
cells
create
entirely
new
class
cellular
medicines
called
red
cell
company
proprietary
red
genetically
engineers
cultures
red
cell
therapeutics
create
selective
potent
allogeneic
cellular
therapies
potential
treatment
cancer
autoimmune
diseases
rubius
initial
product
candidates
designed
activate
expand
immune
system
function
fight
cancer
modulate
immune
system
induce
tolerance
treatment
autoimmune
diseases
information
visit
follow
us
twitter
linkedin
like
us
facebook
forward
looking
statements
press
release
contains
statements
within
meaning
private
securities
litigation
reform
act
amended
including
without
limitation
statements
regarding
expectations
regarding
therapeutic
potential
red
cell
therapeutics
including
expectations
regarding
timing
enrollment
data
success
future
cohorts
phases
clinical
trial
expectations
regarding
therapeutic
potential
timelines
us
file
ind
expectations
regarding
strategy
business
plans
focus
expectations
connection
transition
chief
financial
officer
words
may
could
would
expect
plan
anticipate
intend
believe
estimate
predict
project
potential
continue
target
similar
expressions
intended
identify
statements
although
statements
contain
identifying
words
statements
press
release
based
management
current
expectations
beliefs
subject
number
risks
uncertainties
important
factors
may
cause
actual
events
results
differ
materially
expressed
implied
statements
contained
press
release
including
without
limitation
risks
uncertainties
related
development
red
cell
therapeutic
product
candidates
therapeutic
potential
risks
identified
sec
filings
including
quarterly
report
form
quarter
ended
june
subsequent
filings
sec
risks
uncertainties
related
severity
duration
impact
business
operations
caution
place
undue
reliance
statements
speak
date
made
disclaim
obligation
publicly
update
revise
statements
reflect
change
expectations
events
conditions
circumstances
statements
may
based
may
affect
likelihood
actual
results
differ
set
forth
statements
statements
contained
press
release
represent
views
date
hereof
relied
upon
representing
views
subsequent
date
explicitly
disclaim
obligation
update
statements
contacts
investors
lori
melan√ßon
vice
president
corporate
communications
investor
relations
media
marissa
hanify
director
corporate
communications
dan
budwick
dan
